Research Papers:

Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models

Yushi Qiu, Zhimin Li, John A. Copland, Thomas Mehrling and Han W. Tun _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:28155-28164. https://doi.org/10.18632/oncotarget.25588

Metrics: PDF 1280 views  |   HTML 1682 views  |   ?  


Yushi Qiu1, Zhimin Li1, John A. Copland1, Thomas Mehrling3 and Han W. Tun1,2

1Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA

2Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL 32224, USA

3Mundipharma-EDO GmbH, 4052 Basel, Switzerland

Correspondence to:

Han W. Tun, email: [email protected]

Keywords: EDO-S101; brain tumors; CNS lymphoma; glioblastoma multiforme; metastatic breast cancer of the brain

Received: November 27, 2017    Accepted: May 24, 2018    Published: June 15, 2018


There is a clear unmet need for novel therapeutic agents for management of primary and secondary brain tumors. Novel therapeutic agents with excellent central nervous system (CNS) penetration and therapeutic activity are urgently needed. EDO-S101 is a novel alkylating and histone deacetylase inhibiting agent created by covalent fusion of bendamustine and vorinostat.

We used murine models to perform CNS pharmacokinetic analysis and preclinical therapeutic evaluation of EDO-S101 for CNS lymphoma, metastatic triple-negative breast cancer of the brain, and glioblastoma multiforme. EDO-S101 has excellent CNS penetration of 13.8% and 16.5% by intravenous infusion and bolus administration respectively. It shows promising therapeutic activity against CNS lymphoma, metastatic triple-negative breast cancer of the brain, and glioblastoma multiforme with significant prolongation of survival compared to no-treatment controls. Therapeutic activity was higher with IV infusion compared to IV bolus. It should be evaluated further for therapeutic use in brain tumors.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25588